Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06234423 · ClinicalTrials.gov registry record · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by OnCusp Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
- 15
- Study locations
NCT06234423: Recruiting Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by OnCusp Therapeutics.
NCT06234423 is a Phase 1 study of Ovarian Cancer and Solid Tumor that is actively recruiting participants, run by OnCusp Therapeutics. The registered enrollment target is 263 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (64% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06234423, a Phase 1 study of Ovarian Cancer and Solid Tumor, is actively recruiting participants, sponsored by OnCusp Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Primary Outcome
Type, incidence, and severity of adverse events (AEs) and serious adverse events (SAEs) using the NCI CTCAE v.5.0. Frequency and duration of dose interruptions and reductions.
Conditions Studied
Interventions
- DRUG CUSP06
Study Locations (15)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - Houston
- START San Antonio - San Antonio
Florida
- Mount Sinai Medical Center - Miami Beach
- Florida Cancer Specialists - Sarasota
New York
- NYU Cancer Institute Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 1 |
What NCT06234423 shows while recruiting
NCT06234423 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which CUSP06 is the first listed.
NCT06234423 lists 15 locations in 11 states (Texas, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT06234423 about?
NCT06234423 is a clinical study titled "A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors". This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
What is the current status of trial NCT06234423?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2024-02-09. Estimated completion is 2027-10-31.
What conditions does trial NCT06234423 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumor.
What interventions are being tested in trial NCT06234423?
The interventions under investigation include: CUSP06 (DRUG).
Who is sponsoring clinical trial NCT06234423?
This trial is sponsored by OnCusp Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06234423 being conducted?
This trial has 15 study locations across Colorado, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06234423's enrollment target sits among peer trials
263 79th of 322 higher than 244 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI